Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases.

Creasy JM, Midya A, Chakraborty J, Adams LB, Gomes C, Gonen M, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI, Do RKG, Simpson AL.

Eur Radiol. 2018 Jun 19. doi: 10.1007/s00330-018-5542-8. [Epub ahead of print]

PMID:
29922934
2.

Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention.

Lowery MA, Ptashkin RN, Jordan EJ, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz L, Abou-Alfa GK.

Clin Cancer Res. 2018 May 30. pii: clincanres.0078.2018. doi: 10.1158/1078-0432.CCR-18-0078. [Epub ahead of print]

PMID:
29848569
3.

Microwave Ablation in the Management of Colorectal Cancer Pulmonary Metastases.

Kurilova I, Gonzalez-Aguirre A, Beets-Tan RG, Erinjeri J, Petre EN, Gonen M, Bains M, Kemeny NE, Solomon SB, Sofocleous CT.

Cardiovasc Intervent Radiol. 2018 May 29. doi: 10.1007/s00270-018-2000-6. [Epub ahead of print]

PMID:
29845348
4.

Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?

Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Balachandran VP, Kingham TP, DeMatteo RP, Allen PJ, Blumgart LH, Jarnagin WR, D'Angelica MI.

Surgery. 2018 Jun;163(6):1238-1244. doi: 10.1016/j.surg.2018.01.004. Epub 2018 Feb 15.

PMID:
29455841
5.

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, You D, Viale A, Kemeny N, Segal NH, Stadler ZK, Varghese AM, Kundra R, Gao J, Syed A, Hyman DM, Vakiani E, Rosen N, Taylor BS, Ladanyi M, Berger MF, Solit DB, Shia J, Saltz L, Schultz N.

Cancer Cell. 2018 Jan 8;33(1):125-136.e3. doi: 10.1016/j.ccell.2017.12.004.

PMID:
29316426
6.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
7.

Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control.

Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, Kemeny NE, D'Angelica M, Kingham PT, Solomon SB, Sofocleous CT.

J Vasc Interv Radiol. 2018 Feb;29(2):268-275.e1. doi: 10.1016/j.jvir.2017.08.021. Epub 2017 Dec 6.

PMID:
29203394
8.

The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer.

Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Saltz LB, Balachandran VP, Peter Kingham T, DeMatteo RP, Allen PJ, Jarnagin WR, D'Angelica MI.

Ann Surg Oncol. 2018 Feb;25(2):431-438. doi: 10.1245/s10434-017-6264-x. Epub 2017 Nov 27.

PMID:
29181680
9.

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.

Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI.

J Surg Oncol. 2018 Mar;117(4):634-643. doi: 10.1002/jso.24898. Epub 2017 Nov 22.

PMID:
29165816
10.

Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases.

Shady W, Petre EN, Vakiani E, Ziv E, Gonen M, Brown KT, Kemeny NE, Solomon SB, Solit DB, Sofocleous CT.

Oncotarget. 2017 Aug 2;8(39):66117-66127. doi: 10.18632/oncotarget.19806. eCollection 2017 Sep 12.

11.

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME.

J Am Acad Dermatol. 2017 Sep;77(3):577-579. doi: 10.1016/j.jaad.2017.03.039. No abstract available.

PMID:
28807114
12.

Liver-directed therapy in metastatic colorectal cancer.

Kelly CM, Kemeny NE.

Expert Rev Anticancer Ther. 2017 Aug;17(8):745-758. doi: 10.1080/14737140.2017.1345629. Epub 2017 Jun 28. Review.

PMID:
28636427
13.

Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion.

Zervoudakis A, Boucher T, Kemeny NE.

Visc Med. 2017 Mar;33(1):47-53. doi: 10.1159/000454693. Epub 2017 Feb 3. Review.

14.

Oligometastases of Gastrointestinal Cancer Origin.

Kemeny NE, Rau B.

Visc Med. 2017 Mar;33(1):8-9. doi: 10.1159/000458718. Epub 2017 Feb 22. No abstract available.

15.

A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases.

Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR.

Curr Treat Options Oncol. 2017 Jul;18(7):42. doi: 10.1007/s11864-017-0481-1.

PMID:
28608276
16.

Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer.

Simpson AL, Doussot A, Creasy JM, Adams LB, Allen PJ, DeMatteo RP, Gönen M, Kemeny NE, Kingham TP, Shia J, Jarnagin WR, Do RKG, D'Angelica MI.

Ann Surg Oncol. 2017 Sep;24(9):2482-2490. doi: 10.1245/s10434-017-5896-1. Epub 2017 May 30.

PMID:
28560599
17.

The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature.

Dunphy M, Pandit-Taskar N, Fox JJ, Kemeny N.

AJR Am J Roentgenol. 2017 Jul;209(1):182-186. doi: 10.2214/AJR.16.17560. Epub 2017 May 24.

PMID:
28537788
18.

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R.

Clin Cancer Res. 2017 Aug 15;23(16):4753-4760. doi: 10.1158/1078-0432.CCR-17-0400. Epub 2017 Apr 26.

PMID:
28446505
19.

Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.

Groot Koerkamp B, Sadot E, Kemeny NE, Gönen M, Leal JN, Allen PJ, Cercek A, DeMatteo RP, Kingham TP, Jarnagin WR, D'Angelica MI.

J Clin Oncol. 2017 Jun 10;35(17):1938-1944. doi: 10.1200/JCO.2016.71.8346. Epub 2017 Apr 20.

20.

Robotic hepatic arterial infusion pump placement.

Qadan M, D'Angelica MI, Kemeny NE, Cercek A, Kingham TP.

HPB (Oxford). 2017 May;19(5):429-435. doi: 10.1016/j.hpb.2016.12.015. Epub 2017 Jan 26.

21.

Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.

Connell LC, Boucher TM, Chou JF, Capanu M, Maldonado S, Kemeny NE.

J Surg Oncol. 2017 Mar;115(4):480-487. doi: 10.1002/jso.24536. Epub 2016 Dec 23.

22.

Clinical and genetic determinants of ovarian metastases from colorectal cancer.

Ganesh K, Shah RH, Vakiani E, Nash GM, Skottowe HP, Yaeger R, Cercek A, Lincoln A, Tran C, Segal NH, Reidy DL, Varghese A, Epstein AS, Sonoda Y, Chi D, Guillem J, Temple L, Paty P, Hechtman J, Shia J, Weiser M, Aguilar JG, Kemeny N, Berger MF, Saltz L, Stadler ZK.

Cancer. 2017 Apr 1;123(7):1134-1143. doi: 10.1002/cncr.30424. Epub 2016 Nov 22.

23.

Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.

Cercek A, Boucher TM, Gluskin JS, Aguiló A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D'Angelica M, Kemeny NE.

J Surg Oncol. 2016 Nov;114(6):655-663. doi: 10.1002/jso.24399. Epub 2016 Aug 26.

24.

Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.

Frankel TL, Vakiani E, Nathan H, DeMatteo RP, Kingham TP, Allen PJ, Jarnagin WR, Kemeny NE, Solit DB, D'Angelica MI.

Cancer. 2017 Feb 15;123(4):568-575. doi: 10.1002/cncr.30351. Epub 2016 Oct 13.

25.

Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma.

Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, Jarnagin WR, Ventura A.

PLoS One. 2016 Sep 29;11(9):e0163699. doi: 10.1371/journal.pone.0163699. eCollection 2016.

26.

Young patients with synchronous colorectal liver metastases.

Smith JD, Lowery MA, Fell D, Gallagher DJ, Nash GM, Kemeny NE.

J Surg Oncol. 2016 Apr;113(5):473-6. doi: 10.1002/jso.24181.

27.

Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

Cercek A, Park V, Yaeger R, Reidy-Lagunes D, Kemeny NE, Stadler ZK, Segal NH, Varghese A, Saltz LB.

J Oncol Pract. 2016 May;12(5):e548-53. doi: 10.1200/JOP.2015.008417. Epub 2016 Apr 12.

28.

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL, Kemeny NE, Salo-Mullen EE, Ashraf A, Weiser MR, Garcia-Aguilar J, Robson ME, Offit K, Arcila ME, Berger MF, Shia J, Solit DB, Saltz LB.

J Clin Oncol. 2016 Jun 20;34(18):2141-7. doi: 10.1200/JCO.2015.65.1067. Epub 2016 Mar 28.

29.

Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome.

Sotirchos VS, Petrovic LM, Gönen M, Klimstra DS, Do RK, Petre EN, Garcia AR, Barlas A, Erinjeri JP, Brown KT, Covey AM, Alago W, Brody LA, DeMatteo RP, Kemeny NE, Solomon SB, Manova-Todorova KO, Sofocleous CT.

Radiology. 2016 Sep;280(3):949-59. doi: 10.1148/radiol.2016151005. Epub 2016 Mar 24.

30.

Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.

Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Allen PJ, Fong YC, Cercek A, D'Angelica MI.

J Surg Oncol. 2016 Apr;113(5):477-84. doi: 10.1002/jso.24189. Epub 2016 Feb 2.

31.

Applying tumor genotyping and new clinical approaches to the management of colorectal cancer.

Yaeger RD, Kemeny NE.

J Gastrointest Oncol. 2015 Dec;6(6):644. doi: 10.3978/j.issn.2078-6891.2015.084. No abstract available.

32.

Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR.

Cancer. 2016 Mar 1;122(5):758-65. doi: 10.1002/cncr.29824. Epub 2015 Dec 22.

33.

Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.

Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE.

Clin Colorectal Cancer. 2015 Dec;14(4):296-305. doi: 10.1016/j.clcc.2015.06.003. Epub 2015 Jun 27.

34.

Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D'Angelica MI, Jarnagin WR, Solomon SB, Kemeny NE, Sofocleous CT.

Radiology. 2016 Feb;278(2):601-11. doi: 10.1148/radiol.2015142489. Epub 2015 Aug 12.

35.

Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, DʼAngelica MI.

Ann Surg. 2015 Sep;262(3):476-85; discussion 483-5. doi: 10.1097/SLA.0000000000001427.

36.

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-1706. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

37.

Liver-directed conversion therapy in metastatic colon cancer.

Snyder A, Kemeny N, Shamseddine A, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Gastrointest Oncol. 2015 Jun;6(3):322-8. doi: 10.3978/j.issn.2078-6891.2015.006. No abstract available.

38.

Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.

Correa-Gallego C, Gavane S, Grewal R, Cercek A, Klimstra DS, Gewirtz AN, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N, D'Angelica MI.

HPB (Oxford). 2015 Jul;17(7):644-50. doi: 10.1111/hpb.12421. Epub 2015 May 23.

39.

Metastatic Colorectal Cancer to the Liver: Involve the Surgeon Early and Often.

D'Angelica MI, Kemeny NE.

Ann Surg Oncol. 2015 Jul;22(7):2104-6. doi: 10.1245/s10434-015-4456-9. Epub 2015 Feb 26. No abstract available.

PMID:
25716575
40.

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB.

Clin Cancer Res. 2015 Mar 15;21(6):1313-20. doi: 10.1158/1078-0432.CCR-14-2779. Epub 2015 Jan 14.

41.

Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla.

Sotirchos VS, Petre EN, Brown KT, Brody LA, D'Angelica MI, DeMatteo RP, Kemeny NE, Sofocleous CT.

Case Reports Hepatol. 2014;2014:921406. doi: 10.1155/2014/921406. Epub 2014 Dec 17.

42.

Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection.

Butte JM, Gönen M, Allen PJ, Peter Kingham T, Sofocleous CT, DeMatteo RP, Fong Y, Kemeny NE, Jarnagin WR, D'Angelica MI.

Ann Surg Oncol. 2015 Aug;22(8):2761-71. doi: 10.1245/s10434-015-4370-1. Epub 2015 Jan 9.

43.

RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.

Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N.

Cancer. 2015 Apr 15;121(8):1195-203. doi: 10.1002/cncr.29196. Epub 2014 Dec 9.

44.

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.

Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF.

Genome Biol. 2014 Aug 28;15(8):454. doi: 10.1186/s13059-014-0454-7.

45.

KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong YC, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI.

Cancer. 2014 Dec 15;120(24):3965-71. doi: 10.1002/cncr.28954. Epub 2014 Aug 25.

46.

Postnatal support: who cares?

Kemeny N.

Pract Midwife. 2014 Jul-Aug;17(7):5. No abstract available.

PMID:
25109065
47.

False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.

Litvak A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, Kemeny NE, Weiser MR, Pessin MS, Saltz L.

J Natl Compr Canc Netw. 2014 Jun;12(6):907-13.

PMID:
24925201
48.

Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH.

Urosevic J, Garcia-Albéniz X, Planet E, Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, Mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR, Gomis RR.

Nat Cell Biol. 2014 Jul;16(7):685-94. doi: 10.1038/ncb2977. Epub 2014 Jun 1.

PMID:
24880666
49.

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.

Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB.

Cancer. 2014 Aug 1;120(15):2316-24. doi: 10.1002/cncr.28729. Epub 2014 Apr 15.

50.

Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.

Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D'Angelica MI, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR.

Ann Surg Oncol. 2014 Aug;21(8):2675-83. doi: 10.1245/s10434-014-3649-y. Epub 2014 Mar 25.

Supplemental Content

Loading ...
Support Center